Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Autor: Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., Eertwegh, A. J., Krainer, M., Houédé, Nadine, Santos, R., Mahammedi, H., Ng, S., Maio, M., Franke, F. A., Sundar, S., Agarwal, N., Bergman, A. M., Ciuleanu, T. E., Korbenfeld, E., Sengelov, L., Hansen, S., Logothetis, C., Beer, T. M., McHenry, M. B., Gagnier, P., Liu, D., Gerritsen, W. R., Investigators, C. A.

Publikováno v: Kwon, E D, Drake, C G, Scher, H I, Fizazi, K, Bossi, A, van den Eertwegh, A J M, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Maio, M, Franke, F A, Sundar, S, Agarwal, N, Bergman, A M, Ciuleanu, T E, Korbenfeld, E, Sengeløv, L, Hansen, S, Logothetis, C, Beer, T M, McHenry, M B, Gagnier, P, Liu, D, Gerritsen, W R & CA184-043 Investigators 2014, ' Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 15, no. 7, pp. 700-712 . https://doi.org/10.1016/S1470-2045(14)70189-5
Kwon, E D, Drake, C G, Scher, H I, Fizazi, K, Bossi, A, van den Eertwegh, A J M, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Di Maio, M, Franke, F A, Sundar, S, Agarwal, N, Bergman, A M, Ciuleanu, T E, Korbenfeld, E, Sengelov, L, Hansen, S, Logothetis, C, Beer, T M, McHenry, M B, Gagnier, P, Liu, D & Gerritsen, W 2014, ' Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 15, no. 7, pp. 700-712 . https://doi.org/10.1016/S1470-2045(14)70189-5
Lancet Oncology, 15, 7, pp. 700-12
Lancet Oncology, 15(7), 700-712. Lancet Publishing Group
Lancet Oncology
Lancet Oncology, Elsevier, 2014, 15, pp.700--12. ⟨10.1016/S1470-2045(14)70189-5⟩
Lancet Oncology, 15, 700-12

Item does not contain fulltext BACKGROUND: Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab after radiotherapy in patients with met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae77a6261e49be429378a543af39ccf
https://portal.findresearcher.sdu.dk/da/publications/51fb96bf-6495-4c49-9982-4c82cfe12da9

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Contributions of Ea(z) and Eb(z) MHC genes to lupus susceptibility in New Zealand mice

Autor: Vyse, T. J., Rozzo, S. J., Drake, C. G., Appel, V. B., Lemeur, M., Izui, Shozo, Palmer, E., Kotzin, B. L.

Publikováno v: Journal of Immunology, Vol. 160, No 6 (1998) pp. 2757-2766

Unlike parental New Zealand Black (NZB) or New Zealand White (NZW) mice, (NZB x NZW)F1 mice exhibit a lupus-like disease characterized by IgG autoantibody production and severe immune complex-mediated nephritis. In studies of the genetic susceptibili

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::fc2ae726247d9e7c1c1afa5b9e7216c8
https://pubmed.ncbi.nlm.nih.gov/9510177